Dr. Nicolas Girard, MD, PhD, explores new treatments for advanced HER2-positive non-small cell lung cancer (NSCLC). Highlighting the challenges faced by this orphan patient group, he discusses the use of chemotherapy combined with immune checkpoint inhibitors and emerging HER2-directed agents like T-DXd and poziotinib. Dr. Girard reviews promising response rates from recent studies and addresses the key questions about treatment sequencing and combination strategies. Emphasizing the need for personalized treatment plans, he underscores the importance of ongoing research to improve outcomes for young, non-smoking patients with NSCLC.